Cargando…
The real-world experience with nivolumab in previously treated patients with advanced non-small cell lung cancer from a cancer center in India
BACKGROUND: PDL-1 inhibitors have emerged as the new standard of care for second line treatment of NSCLC. METHODS: Eligible patients included, histologically proven NSCLC, ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1 or 2, age 18 years and above, availability of pre-treatment...
Autores principales: | Abbas, Waseem, Acharya, Rudra Prasad, Pandit, Archit, Gupta, Saurabh, Rao, Ranga Raju |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956575/ https://www.ncbi.nlm.nih.gov/pubmed/31956623 http://dx.doi.org/10.4103/sajc.sajc_111_19 |
Ejemplares similares
-
Value of Precision Medicine in Advanced Non‐Small Cell Lung Cancer: Real‐World Outcomes Associated with the Use of Companion Diagnostics
por: John, Ani, et al.
Publicado: (2020) -
Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States
por: Jahanzeb, Mohammad, et al.
Publicado: (2022) -
ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022) -
Bronchoscopic needle-based confocal laser endomicroscopy (nCLE) as a real-time detection tool for peripheral lung cancer
por: Kramer, Tess, et al.
Publicado: (2022) -
IMPACT OF COVID-19 PANDEMIC ON DIAGNOSIS AND TREATMENT OF LUNG CANCER IN THE VETERAN COHORT
por: ABBAS, HATOON, et al.
Publicado: (2021)